Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Guideline Statement 7 Multimodal pain management approaches (e.g., pharmacological, stress management, manual therapy if available) should be initiated
Health economic analyses, inflammatory markers and other questionnaire data will be reported separately
You can read the abstract at Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial A group of researchers conducted a phase 3 clinical trial to examine the efficacy and safety of subcutaneous semaglutide 2.4 mg once per week, semaglutide 1.0 mg (licensed for the treatment of diabetes), and placebo in managing weight in an adult population who were overweight or obese and have type 2 diabetes
This product is intended exclusively for scientific investigation by qualified laboratories and researchers
